Amphastar Pharmaceuticals, Inc. $AMPH Shares Bought by Systematic Financial Management LP

Key Points

• Systematic Financial Management LP increased its stake in Amphastar Pharmaceuticals by 32.6%, owning a total of 326,546 shares valued at approximately $9.47 million.
• Analysts have mixed ratings for Amphastar, with two analysts giving a Buy rating and two maintaining a Hold rating, resulting in a consensus rating of "Moderate Buy" with an average price target of $31.50.
• Amphastar's stock price increased to $30.50, with a current PE ratio of 11.42 and a market cap of $1.42 billion, reflecting its steady performance despite market fluctuations.

Systematic Financial Management LP raised its position in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH - Free Report) by 32.6% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 326,546 shares of the company's stock after purchasing an additional 80,198 shares during the quarter. Systematic Financial Management LP owned 0.69% of Amphastar Pharmaceuticals worth $9,467,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Signaturefd LLC raised its position in Amphastar Pharmaceuticals by 147.7% in the 1st quarter. Signaturefd LLC now owns 872 shares of the company's stock worth $25,000 after purchasing an additional 520 shares during the period. IFP Advisors Inc purchased a new stake in Amphastar Pharmaceuticals in the 1st quarter worth about $34,000. GF Fund Management CO. LTD. purchased a new stake in Amphastar Pharmaceuticals in the 4th quarter worth about $38,000. GAMMA Investing LLC raised its position in Amphastar Pharmaceuticals by 46.6% in the 1st quarter. GAMMA Investing LLC now owns 1,333 shares of the company's stock worth $39,000 after purchasing an additional 424 shares during the period. Finally, BI Asset Management Fondsmaeglerselskab A S purchased a new stake in Amphastar Pharmaceuticals in the 1st quarter worth about $39,000. 65.09% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of research firms recently weighed in on AMPH. JPMorgan Chase & Co. reissued a "neutral" rating and issued a $30.00 price objective (down from $45.00) on shares of Amphastar Pharmaceuticals in a research report on Monday, May 12th. Wells Fargo & Company reduced their target price on shares of Amphastar Pharmaceuticals from $40.00 to $35.00 and set an "overweight" rating on the stock in a research report on Thursday, May 8th. Bank of America raised their target price on shares of Amphastar Pharmaceuticals from $28.00 to $32.00 and gave the stock a "neutral" rating in a research report on Tuesday. Piper Sandler reduced their target price on shares of Amphastar Pharmaceuticals from $30.00 to $25.00 and set a "neutral" rating on the stock in a research report on Friday, August 8th. Finally, Needham & Company LLC raised shares of Amphastar Pharmaceuticals from a "hold" rating to a "buy" rating and set a $36.00 target price on the stock in a research report on Tuesday, August 12th. Two analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of "Hold" and a consensus target price of $31.60.

Amphastar Pharmaceuticals Stock Up 0.9%

AMPH traded up $0.28 during trading on Friday, hitting $30.54. The stock had a trading volume of 77,667 shares, compared to its average volume of 569,814. The company has a market capitalization of $1.42 billion, a PE ratio of 11.45 and a beta of 0.76. Amphastar Pharmaceuticals, Inc. has a twelve month low of $20.39 and a twelve month high of $53.96. The company has a debt-to-equity ratio of 0.80, a quick ratio of 2.21 and a current ratio of 3.29. The stock has a 50 day simple moving average of $24.48 and a two-hundred day simple moving average of $25.80.

Amphastar Pharmaceuticals Company Profile

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.